Although the anti-tumor effects of paclitaxel result mainly from mitotic arrest, recent evidences suggest alternative mechanisms of cytotoxicity. Cell cycle, cell death and gene expression assays were used to understand the molecular mechanisms of paclitaxel cytotoxicity in breast cancer cells. G 2 /M cell cycle arrest and cell death coincided with the regulation of genes involved in cell death, cell cycle control, microtubule-based processes, oxidative stress, and ubiquitin-proteasome system. Induction of proteasome genes was also correlated with an accumulation of protein for proteasome subunits. Furthermore, a schedule-dependent regulation of paclitaxel-induced cytotoxicity was observed after combining paclitaxel and the proteasome inhibitor MG132. Proteasome inhibition after paclitaxel exposure induced the highest rate of growth inhibition and apoptosis, with no effect on mitotic arrest. These findings give support to clinical combinations of taxanes with proteasome inhibitors, outlining the importance of considering the sequence when designing such regimens.
IntroductIon
The dynamic behavior of microtubules is crucial for their cellular function during mitosis, cell signalling, migration and intracellular trafficking. 1 As these functions are often deregulated in many types of cancer, microtubules are considered compelling cellular targets for chemotherapy. Paclitaxel is one of the most active microtubule-targeting agents against a wide panel of solid tumors, including metastatic breast cancer. [2] [3] [4] It promotes the stable assembly of microtubules from a-and b-tubulin heterodimers and inhibits their de-polymerization, 5 interfering with the formation of the mitotic spindle, and arresting cells at mitosis. Recently, several lines of evidence have suggested that paclitaxel may induce apoptosis through pathways independent of mitotic arrest. 6, 7 However, the exact mechanism by which paclitaxel induces apoptosis is unknown, as well as the antiapoptotic mechanisms activated by cancer cells to evade paclitaxel cytotoxicity.
To better understand the mechanisms of paclitaxel-induced cytotoxicity in breast cancer, we performed a global gene expression analysis in the breast carcinoma cell line MCF7 after exposure to paclitaxel. Main changes included the expected regulation of genes related to M phase arrest, and genes with defined roles in cell death, cell cycle control, microtubule-based processes, oxidative stress, and proteolysis. Remarkably, a significant number of proteasome genes were upregulated after treatment, a finding not described previously in this context. The relevance of this finding was studied by simultaneously targeting the proteasome system in combination with paclitaxel.
MG132 Enhances Paclitaxel Cytotoxicity
Cell cycle analysis and apoptosis detection. Cells were harvested (including detached cells), suspended in PBS, and fixed in 70% ethanol. DNA content was evaluated after propidium iodide staining, and fluorescence-activated cell sorting analysis using a FACScan flow cytometer (Beckton Dickinson, San Diego, CA) and CellQuest software. The Annexin-V-FITC Apoptosis Detection Kit (BD Biosciences) was used to detect apoptosis by flow cytometry. Cells were harvested, and analysed by flow cytometry using simultaneous staining with Annexin-V-FITC and propidium iodide. The SPSS 10.1 software package for Windows (SPSS, Inc., Chicago, IL) was used (T-student) to determine the statistical significance of the relationships between the variables analyzed. In all statistical analyses, results were considered statistically significant at adjusted p value < 0.05.
cDNA microarrays hybridization and data analysis. Total RNA from samples and Universal Human Reference RNA (Stratagene, LaJolla, CA) were used for amplification using the Superscript Choice System (LifeTechnologies, Inc., Gaithersburg, MD) and in vitro transcription with Megascript TM T7 (Ambion, Austin, TX) (previously described in ref. 38) . Data obtained with the Oncochip microarray platform was quantified using the GenePix Pro 6.0 program (Axon Instruments Inc., Union City, CA). Gene ontology was studied with the FatiGo plus programme (babelomics.bioinfo. cipf.es/fatigoplus/cgi-bin/fatigoplus.cgi). The microarrays raw data discussed in this publication have been deposited in NCBIs Gene Expression Omnibus (GEO, www.ncbi.nlm.nih.gov/geo/), and are accessible through GEO Series accession number GSE4298 (submitter H. Hernández-Vargas).
rEsults And dIscussIon
Analysis of gene expression after paclitaxel treatment of MCF7 cells. MCF7 breast cancer cell line is considered sensitive to antimicrotubule drugs. In fact, treatment of MCF7 cells with a clinically achievable concentration of paclitaxel (100 nM) commonly induced G 2 /M cell cycle arrest starting as early as eight hours after exposure. The same concentration produces early apoptosis after 24 hours (as assessed by Annexin-V staining), and ~75% inhibition of growth after 48 hours (Fig. 1A-C) . At eight hours early apoptosis is not different from control cells (less than 1%), and at 48 hours late apoptosis is more evident (15-20% of cells) (data not shown). These time points (i.e., 8, 24 and 48 hours) were selected for studying the transcriptional profile in response to this agent, using cDNA microarray analysis. After normalization and filtering, a total of 313 genes were significantly modified (three-fold induction or repression, relative to non-treated cells) ( Fig. 1 and Suppl. Table 1 ). Only those genes consistently induced or repressed in the three time points analysed (i.e., 8, 24 and 48 hours) were considered as significant. The most representative ontological categories are shown in Figure 1 , including genes related with nucleic acids metabolism, cell death, proteolysis, and mitosis (tubulins, AURKA/STK15, BIRC5/Survivin, BUB1, PHB, PLK1 and PTTG1) ( Table 1) . These findings are relevant, as both, BIRC5 and AURKA / STK15 overexpression, have been related with resistance to paclitaxel. 8, 9 A selected group of genes was validated by RT-PCR or Western blot, including other genes potentially related with resistance to paclitaxel, as the gene coding for the cytosolic protein stathmin (STMN) which acts as a potent regulator of microtubule stability, 10-13 the gene CYP3A4 encoding a member of the cytochrome P450 superfamily of enzymes, known to be involved in the metabolism of approximately half the drugs which are used today, including paclitaxel, [14] [15] [16] the ATP-binding cassette (ABC) transporter MRP5 (ABCC5), involved in multi-drug resistance, 17 and a group of genes related with oxidative stress (PRDX1, SOD1, and WRN) (Suppl. Fig. 1 ). These data shows that potential mechanisms of cell survival are activated in response to paclitaxel exposure in MCF7 cells.
The ubiquitin-proteasome system is composed of an ubiquitination function and a 26 S proteasome degradation function. Interestingly, genes in both categories were found to be highly regulated after paclitaxel exposure, including the transcripts for the E2 ubiquitin-conjugating enzymes UBE2N and UBE2C, and the proteasome subunits b6 (anti-C2) and a2 (anti-C5) (Suppl. Fig. 1 ). Protein accumulation of proteasome subunits was not observed after equitoxic concentrations of related and non-related drugs, including docetaxel, 5-fluorouracil and gemcitabine (data not shown). However, proteasome subunits were also increased in the non-related breast carcinoma cell line MDA-MB-231 after paclitaxel (Suppl. Fig. 1 ). These data suggest that the paclitaxel-dependent induction of proteasome subunits is drug-specific and not restricted to one cell line.
Sequence dependent interaction of the proteasome inhibitor MG132 and paclitaxel in MCF7 cells. Because of its representation in the global expression profile, proteasome-related genes were selected for further functional validation. As proteasome activation is instrumental to a variety of fundamental cellular processes, 18, 19 it could be a mechanism of cell survival in response to paclitaxel exposure. To determine whether the inactivation of the proteasome could lead to sensitisation of cancer cells to paclitaxel, we conducted cell growth assays with simultaneous exposure to MG132, a specific inhibitor of the proteasome. 20 Since proteasome inhibitors and paclitaxel are cell cycle-specific agents, the disturbances of the cell cycle produced by these agents may influence the growth inhibitory effects of each other, in such a way that the drug schedule may play a significant role in the outcome. For this reason, several combinations of paclitaxel and MG132 were evaluated. A schedule-dependent enhancement by MG132 was observed only when its administration was preceded by paclitaxel exposure (PTX12g MG12, p < 0.001, Fig. 2 ). This enhancement of cell growth inhibition induced by MG132 seems to be specific for paclitaxel, as no effect was observed for other microtubule targeting agents like colcemide and docetaxel, or the unrelated drugs, 5-Fluorouracil and Gemcitabine (Fig. 3) . However, as changes in the concentration of taxanes can influence the mechanism of action of these agents, [21] [22] [23] more studies are required to rule out a similar mechanism at different concentrations of docetaxel.
Interestingly, the opposite combination (i.e., proteasome inhibition followed by paclitaxel exposure) produced significantly less inhibition of cell growth (MG132g PTX, p < 0.05, Fig. 2) .
These results supporting proteasome activation as a mechanism of defence against paclitaxel, are in agreement with a recent study using a truncated version of human TRIP1 (an ATPase subunit of the 19S proteasome regulatory complex). 24 Stable expression of this protein had a dominant-negative effect on proteasome activity and enhanced the apoptotic response to spindle poisons. In addition, a recent investigation suggested that proteasome inhibitors may trigger generation of ROS by altering mitochondrial membrane potential and inducing release of cytochrome c. 25 As paclitaxel is also able to induce oxidative stress, proteasome inhibitors may enhance paclitaxel-induced apoptosis via additional generation of ROS.
Proteasome inhibitor MG132 increases paclitaxel-dependent apoptosis without affecting cell cycle arrest in mitosis. To understand the mechanisms by which MG132 enhances paclitaxel-dependent inhibition of cell growth, we studied cell cycle and cell death using the same combinations of both agents. MG132 alone induced a G 2 /M cell cycle arrest in MCF7 cells (Fig. 4) , although this effect was not observed when added after 12 hours of paclitaxel exposure, i.e., G 2 /M arrest induced by paclitaxel was dominant in this condition. In any other combination of drugs, the effect of MG132 on cell cycle was dominant. Most interesting, although MG132 did not induce apoptosis by itself, as assessed by Annexin-V staining ( Fig. 4A and B) , it did enhance paclitaxel-induced apoptosis when administered after 12 hours of paclitaxel treatment (19% vs. 28%, p < 0.05). Moreover, accumulation of phospho-H2AX was in accordance for these cells being committed to apoptosis (Fig. 4C) . In contrast, when MG132 was administered before paclitaxel or when both drugs were administered together during 24 hours, the effect on paclitaxel-dependent apoptosis was the opposite, with a clear reduction of Annexin-V positive cells (from 19% with paclitaxel it was reduced to 4.4% and 4.2%, when MG132 was administered before or simultaneously with paclitaxel, respectively, p < 0.05), and decreased phospho-H2AX accumulation ( Fig. 4B and C) .
These results indicate that MG132, when used alone, acts predominantly as an inhibitor of proliferation by inducing cell cycle delay and no cell death. However, when administered after paclitaxel, MG132 is able to enhance the induction of apoptosis after 24 hours. In any other combination MG132 acts by inhibiting paclitaxel-induced apoptosis. Because of the cell cycle-specificity of both types of drugs, 26, 27 one agent might reduce the cytotoxicity by preventing cells from entering the specific phase in which they are most sensitive to the other agent. It has been described that paclitaxel-dependent cytotoxicity requires cells to be first arrested at mitosis and upon mitotic slippage to enter apoptotic cell death. 27 Although this mechanism is not fully understood, it is possible that MG132 counteracts paclitaxel-induced apoptosis when administered in first place by arresting cells before entering mitosis. In fact, with any other combination of both agents, arrest in mitosis was avoided, as assessed with the mitotic marker MPM-2 (Fig. 4C) . When administered after 12 hours of paclitaxel treatment, most cells have already reached 4n-DNA content, and that opposing effect is avoided. A similar inhibition of mitotic arrest by MG132 was observed in MDA-MB-231 cells (Suppl. Fig. 2) . In this sense, other drugs have shown a schedule dependent efficacy when combined with paclitaxel, through a similar mechanism. 28 In addition, p21 induction by MG132 can attenuate mitochondrial injury and apoptosis induced by paclitaxel, as has been shown in human cells. 29, 30 On the other hand, the enhancement of apoptosis observed with MG132 could be specific for cells in mitosis, explaining the higher response when cells are previously arrested in M phase with paclitaxel. Finally, it is possible that proteasome activity is required in an initial phase of paclitaxel-induced cytotoxicity, potentially involved in the degradation of anti-apoptotic proteins. After this initial phase, proteasome inhibition will prevent the degradation of pro-apoptotic proteins (as those of the Bcl2 family), enhancing the induction of apoptosis, a biphasic mode of proteasome action that has been recently described (refs. 31 and 32) . One interesting possibility in this direction has been described in recent studies linking the BH3-only pro-apoptotic protein Bim with the induction of apoptosis by paclitaxel in cancer cell lines. 33, 34 As Bim is targeted for degradation by the proteasome, the combination of paclitaxel with the proteasome inhibitor PS-341 (bortezomib, Velcade) abrogated paclitaxel resistance and promoted tumor regression. 35 Despite its success, the overall response rate for paclitaxel still remains under 50% in patients with advanced metastatic breast cancer. 36 The elucidation of the molecular pathways involved in paclitaxel cytotoxicity, as those related with proteasome function, will aid in the understanding of its mechanism of action and the identification of novel targets for chemotherapy. The current availability of proteasome inhibitors, as the specific inhibitor PS-341, makes these findings significant for future clinical trials, as better drug combinations and therapeutic schedules considering sequential treatments can be rationally designed. . Cell growth after several combinations of 100 nM paclitaxel, and 10 mM of the proteasome inhibitor MG132. For sequential combinations 12 hours of treatment with one agent preceded a second 12-hour period of treatment with the second agent. For the remaining conditions 24 hour treatments were performed. Cell growth was assessed by crystal violet assay, as described in Materials and Methods. Each condition of treatment was performed in five independent experiments. Statistical significance is shown for paclitaxel alone compared to MG132 followed by paclitaxel (**p < 0.005), and paclitaxel followed by MG132 (***p < 0.001). 
